On November 20, 2024, more than 80 leaders in rare cancer came together for TCF’s 3rd Think Tank on Advancing Precision Medicine in Rare Cancers to listen, learn, and collaborate. The event featured a patient keynote speaker, multiple scientific panels, a patient case presentation by TRACK’s Molecular Tumor Board, and a discussion with patient advocates about their work to drive rare cancer research forward.
Recordings of select sessions are available to watch, below.
The Precision Patient: Seeking Out Innovative, Science-Based Therapy for Patients with Rare Cancers
Featuring Allen Chankowsky, Keynote Speaker
Allen Chankowsky, a rare cancer patient, international advocate and author, presents his unique experience learning and advocating for a treatment protocol outside of the standard of care therapy for his rare cancer.
N-of-1 Patient Centric Clinical Trials
Featuring Razelle Kurzrock, MD
Dr. Razelle Kurzrock, a leader in rare cancer research and care, presents her groundbreaking work in patient-centered rare cancer clinical trials.
Revolutionizing Rare Cancer Drug Development with Novel Tumour-Agnostic Classifiers & AI Innovations
Featuring Vivek Subbiah, MD
Dr. Vivek Subbiah, a leader in rare cancer clinical care, presents his work and perspectives on the critical importance of tissue-agnostic therapies for patients with rare cancers.
The Power of Personal Experience: Patients and Caregivers as Drivers of Rare Cancer Research
The panel discussion featured the perspectives and insights of advocacy organization leaders and caregivers Kristen Palma (President, TargetCancer Foundation), Michael Casaus (Co-Founder, cureMEC: The Myoepithelial Carcinoma Project), and Suzanne Vincze (Vice President, Max Vincze Foundation).
Success Stories & Ethics of Expanded Germline & Cascade Testing in Pediatric Cancer
Catherine Skefos, a senior genetic counselor for both pediatric and adult oncology, presented on germline testing considerations for at-risk relatives of hereditary pediatric cancer syndromes.
Closing the Book on Readers and Writers in NUT Carcinoma
Dr. Christopher A. French, a leading expert in a rare and lethal cancer known as NUT midline carcinoma (NMC), discussed the molecular genetics of NUT carcinoma and potential targeted therapies.
Thank You To Our Sponsors
